Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2

Ravi Ojha; Jesse Pyle; Olli Vapalahti; Giuseppe Balistreri; Tom Kirchhausen.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-446623

Documentos relacionados

  1. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
  2. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.
  3. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
  4. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  5. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
  6. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
  7. Mechanisms of SARS-CoV-2 entry into cells.
  8. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
  9. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry.
  10. In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain.